New Jersey: This weekend, at the international headache meeting in Copenhagen (EHMTIC*), electroCore will be presenting full data on their PREVA study, a randomized, multi-center trial across several European countries, which showed that preventative use of non-invasive vagus nerve stimulation (nVNS) can substantially reduce the frequency of cluster headache attacks (i.e., by 43.4%) versus the control group (the current standard of care, which experienced only a 12% reduction).

Three poster presentations will provide full details of the PREVA trial and include

A report on – the randomized phase

A report on the open label phase

An analysis of quality of life impact

On Saturday evening electroCore is hosting a satellite symposium with three eminent headache specialists.

·         Professor Jean Schoen, Director of the Headache Research Unit at the University of Liège, Belgium, who will provide an overview of Neuromodulation and the role of non-invasive vagus nerve (nVNS) stimulation.

·         Dr. Charly Gaul, Director of the Migraine and Headache Clinic Königstein, Germany and the principle investigator of the PREVA trial who will comprehensively explore the use of nVNS in the prevention of cluster headache.

·         Professor Stephen Silberstein, Director of the Thomas Jefferson Headache Centre at the Thomas Jefferson University and Hospitals Philadelphia, who will present data on nVNS in the prevention of chronic migraine.

electroCore, a US based company, has developed non-invasive Vagus Nerve Stimulation (nVNS) therapies, which are self-administered by patients for the treatment of multiple conditions in neurology, psychiatry, respiratory and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in gastric motility disorders and epilepsy.

In Europe, electroCore’s nVNS technology has a CE mark for primary headache, bronchoconstriction, epilepsy, gastric motility disorders, and anxiety and depression. It also has regulatory approval for the acute and/or prophylactic treatment of cluster headache, migraine and medication overuse headache in South Africa, India, New Zealand, Australia, Colombia, Brazil and Malaysia, and in Canada for cluster headache. US approval is anticipated in 2015.